New and candidate vaccines for gastrointestinal infections

Current Opinion in Gastroenterology

Volumn 26, Issue 1, 2010, Pages 12-16

  Simon, Jakub ^a   Kotloff, Karen ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical study; Diarrhea; Enteric vaccine; Immune correlate; Live attenuated

Indexed keywords

ANTIGEN; BACTERIAL VACCINE; CHOLERA VACCINE; ENTEROTOXIN VACCINE; SHIGELLA VACCINE; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; BACTERIAL IMMUNITY; CHOLERA; CLINICAL TRIAL; DIARRHEA; GASTROINTESTINAL INFECTION; HUMAN; IMMUNIZATION; NONHUMAN; REVIEW; SHIGELLOSIS; VACCINATION;

ANIMALS; BACTERIAL INFECTIONS; BACTERIAL VACCINES; CLINICAL TRIALS AS TOPIC; COMMUNICABLE DISEASE CONTROL; FORECASTING; GASTROENTERITIS; HUMANS; PROGNOSIS; VACCINATION; VACCINES, ATTENUATED; VIRAL VACCINES; VIRUS DISEASES; WORLD HEALTH ORGANIZATION;

EID: 74249091695     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e328333f8ee     Document Type: Review

References (45)

1. Boschi-Pinto C, Velebit L, Shibuya K. Estimating child mortality due to diarrhoea in developing countries. Bull World Health Organ 2008; 86:710-717.
2. Petri WA Jr, Miller M, Binder HJ, et al. Enteric infections, diarrhea, and their impact on function and development. J Clin Invest 2008; 118:1277-1290.
3. Gascon J. Epidemiology, etiology and pathophysiology of traveller's diarrhea. Digestion 2006; 73 (Suppl 1):102-108.
4. Levine MM. Enteric infections and the vaccines to counter them: future directions. Vaccine 2006; 24:3865-3873.
5. Bhutta ZA, Threlfall J. Addressing the global disease burden of typhoid fever. JAMA 2009; 302:898-899.
6. Lynch MF, Blanton EM, Bulens S, et al. Typhoid fever in the United States, 1999-2006. JAMA 2009; 302:859-865.
7. Asrat D. Shigella and Salmonella serogroups and their antibiotic susceptibility patterns in Ethiopia. East Mediterr Health J 2008; 14:760-767.
8. Mendez AE, Pitart C, Ruiz J, et al. Evolution of antimicrobial resistance in enteroaggregative Escherichia coli and enterotoxigenic Escherichia coli causing traveller's diarrhoea. J Antimicrob Chemother 2009; 64:343-347.
9. Musiime V, Kalyesubula I, Kaddu-Mulindwa D, Byarugaba J. Enteric bacterial pathogens in HIV-infected children with acute diarrhea in Mulago referral and teaching hospital, Kampala, Uganda. J Int Assoc Physicians AIDS Care (Chic Ill) 2009; 8:185-190.
10. Shaheen HI, bdel Messih IA, Klena JD, et al. Phenotypic and genotypic analysis of enterotoxigenic Escherichia coli in samples obtained from Egyptian children presenting to referral hospitals. J Clin Microbiol 2009; 47:189-197.
11. Department of Immunization, Vaccines, and Biologicals, WHO. Rotavirus surveillance: worldwide, 2001-2008. MMWR Morb Mortal Wkly Rep 2008; 57:1255-1257.
12. Sanchez-Padilla E, Grais RF, Guerin PJ, et al. Burden of disease and circulating serotypes of rotavirus infection in sub-Saharan Africa: systematic review and meta-analysis. Lancet Infect Dis 2009; 9:567-576.
13. Meeting of the Immunization Strategic Advisory Group of Experts, April 2009: conclusions and recommendations. Wkly Epidemiol Rec 2009; 84:220-236.
14. Meeting of the Diarrhoeal and Enteric Vaccines Advisory Committee, October 2008: executive summary. Wkly Epidemiol Rec 2009; 84:30-36.
15. Takahashi I, Nochi T, Yuki Y, Kiyono H. New horizon of mucosal immunity and vaccines. Curr Opin Immunol 2009; 21:352-358.
16. Kweon MN. Shigellosis: the current status of vaccine development. Curr Opin Infect Dis 2008; 21:313-318.
17. Levine MM, Kotloff KL, Barry EM, et al. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat Rev Microbiol 2007; 5:540-553.
18. Liu J, Sun Y, Feng S, et al. Towards an attenuated enterohemorrhagic Escherichia coli O157:H7 vaccine characterized by a deleted ler gene and containing apathogenic Shiga toxins. Vaccine 2009; 27:5929-5935.
19. Fang CM, Wang JY, Chinchilla M, et al. Use of mchI encoding immunity to the antimicrobial peptide microcin H47 as a plasmid selection marker in attenuated bacterial live vectors. Infect Immun 2008; 76:4422-4430.
20. Morin CE, Kaper JB. Use of stabilized luciferase-expressing plasmids to examine in vivo-induced promoters in the Vibrio cholerae vaccine strain CVD 103-HgR. FEMS Immunol Med Microbiol 2009; 57:69-79.
21. Robbins JB, Kubler-Kielb J, Vinogradov E, et al. Synthesis, characterization, and immunogenicity in mice of Shigella sonnei O-specific oligosaccharidecore- protein conjugates. Proc Natl Acad Sci U S A 2009; 106:7974-7978.
22. Hassane FS, Phalipon A, Tanguy M, et al. Rational design and immunogenicity of liposome-based diepitope constructs: application to synthetic oligosaccharides mimicking the Shigella flexneri 2a O-antigen. Vaccine 2009; 27:5419-5426.
23. Pore D, Chowdhury P, Mahata N, et al. Purification and characterization of an immunogenic outer membrane protein of Shigella flexneri 2a. Vaccine 2009; 27:5855-5864.
24. Yuki Y, Tokuhara D, Nochi T, et al. Oral MucoRice expressing double-mutant cholera toxin A and B subunits induces toxin-specific neutralising immunity. Vaccine 2009; 27:5982-5988.
25. Glass RI, Svennerholm AM, Khan MR, et al. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J Infect Dis 1985; 151:236-242.
26. Tacket CO, Cohen MB, Wasserman SS, et al. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination. Infect Immun 1999; 67:6341-6345.
27. Kantele A. Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine. Vaccine 1990; 8:321-326.
28. Kotloff KL, Losonsky GA, Nataro JP, et al. Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2. Vaccine 1995; 13:495-502.
29. Cohen D, Green MS, Block C, et al. Natural immunity to shigellosis in two groups with different previous risks of exposure to Shigella is only partly expressed by serum antibodies to lipopolysaccharide [letter]. J Infect Dis 1992; 165:785-787.
30. McKenzie R, Bourgeois AL, Frech SA, et al. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine 2007; 25:3684-3691.
31. Frech SA, DuPont HL, Bourgeois AL, et al. Use of a patch containing heatlabile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet 2008; 371: 2019-2025.
32. Glenn GM, Francis DH, Danielsen EM. Toxin-mediated effects on the innate mucosal defenses: implications for enteric vaccines. Infect Immun 2009; 77:5206-5215.
33. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008; 47:401-409.
34. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 2007; 25:5467-5484.
35. Saha D, LaRocque RC, Khan AI, et al. Incomplete correlation of serum vibriocidal antibody titer with protection from Vibrio cholerae infection in urban Bangladesh. J Infect Dis 2004; 189:2318-2322.
36. Harris JB, LaRocque RC, Chowdhury F, et al. Susceptibility to Vibrio cholerae infection in a Cohort of Household Contacts of Patients with Cholera in Bangladesh. PLoS Negl Trop Dis 2008; 2:e221.
37. Sztein MB. Cell-mediated immunity and antibody responses elicited by attenuated Salmonella enterica Serovar Typhi strains used as live oral vaccines in humans. Clin Infect Dis 2007; 45 (Suppl 1):S15-S19.
38. Tacket CO, Sztein MB, Losonsky GA, et al. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol 2003; 108:241-247.
39. Samandari T, Kotloff KL, Losonsky GA, et al. Production of IFN-gamma and IL-to Shigella invasins by mononuclear cells from volunteers orally inoculated with a Shiga toxin-deleted Shigella dysenteriae type 1 strain. J Immunol 2000; 164:2221-2232.
40. Jayasekera CR, Harris JB, Bhuiyan S, et al. Cholera toxin-specific memory B cell responses are induced in patients with dehydrating diarrhea caused by Vibrio cholerae O1. J Infect Dis 2008; 198:1055-1061.
41. Simon JK, Wahid R, Maciel M Jr, et al. Antigen-specific B memory cell responses to lipopolysaccharide (LPS) and invasion plasmid antigen (Ipa) B elicited in volunteers vaccinated with live-attenuated Shigella flexneri 2a vaccine candidates. Vaccine 2009; 27:565-572.
42. Harris AM, Bhuiyan MS, Chowdhury F, et al. Antigen-specific memory B-cell responses to Vibrio cholerae O1 infection in Bangladesh. Infect Immun 2009; 77:3850-3856.
43. Kanungo S, Paisley A, Lopez AL, et al. Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial. Vaccine 2009; 27:6887-6893.
44. Zhou WZ, Koo HW, Wang XY, et al. Revaccination with locally-produced vi typhoid polysaccharide vaccine among Chinese school-aged children: safety and immunogenicity findings. Pediatr Infect Dis J 2007; 26:1001-1005.
45. Cook J, Jeuland M, Whittington D, et al. The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries. Vaccine 2008; 26:6305-6316.